Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 369-377 , December 2009

Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution

  • Anna Valeria Vergoni, MD

      Affiliations

    • Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    • ,
  • Giovanni Tosi, PhD

      Affiliations

    • Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    • ,
  • Raffaella Tacchi, MD

      Affiliations

    • Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    • ,
  • Maria Angela Vandelli, PhD

      Affiliations

    • Division of Toxicology and Clinical Pharmacology, University of Modena and Reggio Emilia, Modena, Italy
    • Corresponding Author InformationCorresponding author: Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy.
    • ,
  • Alfio Bertolini, MD

      Affiliations

    • Division of Toxicology and Clinical Pharmacology, University of Modena and Reggio Emilia, Modena, Italy
    • ,
  • Luca Costantino, PhD

      Affiliations

    • Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, Modena, Italy

Received 29 September 2008 ,Accepted 16 February 2009.

References 

  1. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci. 2003;6:252–273
  2. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008;5:155–174
  3. Kerns E, Di L. Blood brain barrier. In: Drug-Like Properties: Concepts, Structure Design and Methods. San Diego, CA: Academic Press; 2008;p. 122–136
  4. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release. 2005;108:84–96
  5. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release. 2007;122:1–9
  6. Castro DJ, Haghighat S, Saxton RE, Reisler E, Jongwaard N, Castro DJ, et al. Biodistribution of Rhodamine-123 in nude mice heterotransplanted with human squamous cell carcinomas. Laryngoscope. 1992;10:868–874
  7. de Lange EC, de Bock G, Shinkel AH, de Boer AG, Breimer DD. BBB transport using MDR 1A–/– and wild-type mice. Total brain versus microdialysis concentration profiles of Rhodamine-123. Pharm Res. 1998;15:1657–1665
  8. Harapanhalli RS, Roy AM, Aldestein SJ, Kassis AI. [125I/127I/131I]Iodorhodamine: synthesis, cellular localization and biodistribution in athymic mice bearing human tumor xenografts and compartison with [99mTc]-Hexakis-(2-methoxyisobutylisonitrile). J Med Chem. 1998;41:2111–2117
  9. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int J Pharm. 2005;298:274–292
  10. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14:325–328
  11. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharm Exp Ther. 2006;317:1246–1253
  12. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release. 2007;118:54–58
  13. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2008;349:249–255
  14. Ma W, Yuan X, Kang C, Su T, Yuan X, Pu P, et al. Evaluation of blood circulation of polysaccharide surface-decorated PLA nanoparticles. Carbohyd Polymers. 2008;72:75–81
  15. Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuan WF, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001;71:203–211
  16. Gref R, Minamitake Y, Peracchia MT, Trubeskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600–1603
  17. Nam YS, Park Y, Han SH, Chang IS. Intracellular drug delivery using poly(d,l-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol Lett. 2003;24:2093–2098
  18. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29:4429–4438
  19. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2008;134(1):55–61
  20. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1–R4
  21. Chen H, Gaul F, Gou D, Maycock A. Determination of loperamide in rat plasma and bovine serum albumin by LC. J Pharm Biomed Anal. 2000;22:555–561
  22. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1997;
  23. Eddy NB, Leimbach D. Synthetic analgesic. II. Dithienylbutyl and dithienylbutylamines. J Pharm Exp Ther. 1953;107:385–395
  24. Rezayat M, Rahnavard A, Zarrindast M. Role of cholecystokinin receptors in induction of antinociception in hot-plate test. Pharmacol Toxicol. 2000;87:58–62
  25. Rafati H, Coombes AGA, Adler A, Holland J, Davis SS. Protein-loaded poly(d,l-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics. J Control Release. 1997;43:89–102
  26. Huang X, Chestang BL, Brazel CS. Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking. Int J Pharm. 2002;248:183–192
  27. Cohen S, Yoshioka T, Lucarelli M, Huang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8:713–720
  28. Sah HK, Toddywala R, Chien YW. The influence of biodegradable microcapsule formulations on the controlled release of a protein. J Control Release. 1994;30:201–211
  29. Batycky RP, Hanes J, Langer R, Edwards DA. A theoretical model of erosion and macromolecular release from biodegrading microspheres. J Pharm Sci. 1997;86:1464–1477
  30. Uchida K, Yagi A, Oda Y, Goto S. Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by and oil-in-oil (o/o) solvent evaporation method. J Microencaps. 1996;13:509–518
  31. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithkissios DS, Avgoustakis K. Effect on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm. 2001;221:143–152
  32. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as a new drug carrier for brain delivery. Pharm Res. 2001;18:1157–1166
  33. Schroeder U, Sabel BA. Body distribution of 3H-labelled dalargin bound to poly(butylcyanoacrylate) nanoparticles after i.v. injection to mice. Life Sci. 2000;66:495–502
  34. LeRay AM, Vert M, Gautier JC, Benoit JP. Fate of 14C poly(d,l-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int J Pharm. 1994;106:201–211
  35. Lode J, Fichtner I, Kreuter J, Berndt A, Diederichs JE, Reszka R. Influence of surface-modifying surfactants on the pharmacokinetic behaviour of 14C-poly(methylmetacrylate) nanoparticles in experimental tumor models. Pharm Res. 2001;18:1613–1619
  36. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J. Biodistribution of polysorbate-80 coated doxorubicin loaded 14C -poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target. 2006;14:97–105
  37. Brigger P, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P, et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther. 2002;303:928–936
  38. Brigger I, Morizet J, Laudani L, Aubert G, Appel M, Velasco V, et al. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release. 2004;100:29–40

 No conflict of interest was reported by the authors of this paper.

PII: S1549-9634(09)00059-8

doi: 10.1016/j.nano.2009.02.005

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 369-377 , December 2009

Article Tools

* Image Usage & Resolution